GlassScriptPhysician profile
Thomas M Tann
NPI 1083654578
$4,461.05
in general payments reported to CMS, 2019-2025
32 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $220 · 2021: $398 · 2022: $499 · 2023: $1,047 · 2024: $873 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,951 · Entertainment: $30.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.84 |
| Entertainment | $30.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $590.35 | 2019-2025 | Clareon, Centurion, Rocklatan |
| Abbvie INC. | $477.63 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Glaukos Corporation | $349.26 | 2019-2025 | Idosetr, Ce-Marked Kxla System, Istent Trabecular Micro-Bypass System Model Is3 |
| Johnson & Johnson Surgical Vision, INC. | $336.00 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Mallinckrodt Hospital Products INC. | $299.21 | 2021-2025 | Acthar |
| Rxsight INC | $231.37 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Amgen INC. | $230.68 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $222.45 | 2020-2023 | |
| Oyster Point Pharma, INC. | $221.79 | 2022-2024 | Tyrvaya |
| Rayner Intraocular Lenses Limited | $216.56 | 2022-2024 | Omidria, Rayone Aspheric, Rayone Spheric |
| Omeros Corporation | $213.03 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $172.39 | 2022-2025 | Vyzulta, Stellaris, Envista Envy Iol |
| Allergan, INC. | $142.19 | 2019-2021 | |
| Horizon Therapeutics Plc | $116.11 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $63.95 | 2019-2023 | Cequa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $58.77 | 2024-2025 | Purified Cortrophin Gel |
| Aerie Pharmaceuticals, INC. | $49.33 | 2019-2020 | |
| Sight Sciences, INC. | $49.06 | 2022-2024 | Omni Surgical System |
| Biotissue Holdings INC. | $48.73 | 2022 | |
| Iridex Corporation | $47.13 | 2021-2023 | |
| Nova Eye, INC. | $43.32 | 2024-2025 | |
| Ivantis, INC | $39.42 | 2020-2021 | |
| Dompe US, INC. | $38.36 | 2021-2022 | |
| Thea Pharma INC. | $37.46 | 2025 | Iyuzeh |
| Apellis Pharmaceuticals, INC. | $26.24 | 2023 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $25.58 | 2024 | Xdemvy |
| Ocular Therapeutix, INC. | $23.72 | 2023 | Dextenza |
| Harrow Eye, LLC | $20.57 | 2025 | Triesence |
| Beaver-Visitec International, INC. | $18.90 | 2020 | |
| Halozyme INC | $18.07 | 2023 | |
| Genentech USA, INC. | $18.06 | 2024 | Vabysmo |
| Eyepoint US, INC. | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.